Our Company

Transforming Scientific Advancements into better Life Science solutions for tomorrow.

Bioneer is a Danish CRO and CDMO delivering high-quality solutions to biotech and pharmaceutical companies worldwide. From our base in Medicon Valley, we combine Nordic quality standards with deep expertise to support early-stage drug discovery, development, and manufacturing.

With a 40-year proven track record as a government-approved Research and Technology Organization, we each year support more than 300 projects and contribute to 30+ scientific publications, reflecting our strong foundation in applied research and industry collaboration.

Our core capabilities include in vitro disease modelling, drug formulation, and recombinant protein development and manufacturing. Where relevant, we apply advanced in vitro approaches aligned with the regulatory guidance to reduce reliance on animal testing and the 3Rs principles.

We help you, our partners:

  • discover, develop and produce promising early drug candidates and recombinant proteins
  • generate preclinical insights into mechanisms of action, efficacy, safety, and formulation

Our approach is human-first and pragmatic, combining scientific expertise with flexibility, transparent communication, and a focus on delivering quality data and results that accelerate your projects.

Bioneer is a Danish CRO and CDMO delivering high-quality solutions to biotech and pharmaceutical companies worldwide.

From our base in Medicon Valley, we combine Nordic quality standards with deep expertise to support early-stage drug discovery, development, and manufacturing.

With a 40-year proven track record as a government-approved Research and Technology Organization, we each year support more than 300 projects and contribute to 30+ scientific publications, reflecting our strong foundation in applied research and industry collaboration.

Our core capabilities include in vitro disease modelling, drug formulation, and recombinant protein development and manufacturing.

Where relevant, we apply advanced in vitro approaches aligned with the regulatory guidance to reduce reliance on animal testing and the 3Rs principles.

We help you, our partners:

  • discover, develop and produce promising early drug candidates and recombinant proteins
  • generate preclinical insights into mechanisms of action, efficacy, safety, and formulation

Our approach is human-first and pragmatic, combining scientific expertise with flexibility, transparent communication, and a focus on delivering quality data and results that accelerate your projects.

Locations

Bioneer is located in the heart of Medicon Valley.
We have two sites in Denmark serving our partners globally.

Hørsholm – Denmark

Our main site and headquarters is located in Hørsholm, 20 minutes north of Copenhagen, in the heart of the Scion-DTU Science Park.
This 3350m2 site is equipped with both offices and state-of-the-art lab facilities. Overall the site has 1400m2 office space, 450m2 of warehouse and 1500m2 of laboratory space.

Copenhagen – Denmark

We have a site located at the Department of Pharmacy at the University of Copenhagen, Bioneer:FARMA.
This 180m2 site has offices and laboratories, It was established in 2007 in collaboration with the University of Copenhagen.

Hørsholm – Denmark

Our main site and headquarters is located in Hørsholm, 20 minutes north of Copenhagen, in the heart of the Scion-DTU Science Park.
This 3350m2 site is equipped with both offices and state-of-the-art lab facilities. Overall the site has 1400m2 office space, 450m2 of warehouse and 1500m2 of laboratory space.

Copenhagen – Denmark

We have a site located at the Department of Pharmacy at the University of Copenhagen: Bioneer:FARMA.
This 180m2 site has offices and laboratories. It was established in 2007 in collaboration with the University of Copenhagen.

Leadership

Our dedicated team is looking forward to adding value to your programs.

Jakob Oemar Gjørret
Jakob Oemar GjørretCEO, Ph.D.

As CEO of Bioneer, Jacob Oemar Gjørret is guiding our leadership team and specialists’ efforts in the strategic development and growth of Bioneer.

Jakob Gjørret brings 20+ years of experience and a track record in strategic, operational, and leadership roles.

Jakob is a trained Doctor of Veterinary Medicine (DVM) and holds a Ph.D. in embryonic stem cell biology from the Royal Veterinary and Agricultural University (KVL) at the University of Copenhagen, Denmark, where he held a position as an assistant professor before pursuing an industry career.

Prior to joining Bioneer as CEO, he has served in various scientific, leadership, and commercial roles, first in R&D and Strategic Alliance Management in the diagnostic industry (Dako, later Agilent), followed by a senior leadership position in the laboratory service industry (Unilabs). This has since been complemented by hands-on experience in drug development in the pharma industry (Novo Nordisk) as a diagnostic development lead.

Jakob brings strong scientific, commercial, and operational understanding of how to effectively create and deliver customer value in science-based services.

Christian Clausen
Christian ClausenCSO, M.Sc.

Christian Clausen was educated in biochemistry and medical science at the University of Southern Denmark and Odense University Hospital, with research visits at Aarhus University Hospital. He has also completed R&D management programs at Harvard Business School, Boston. His research experience is primarily in the human cell biology field, especially in developing in vitro model systems and recombinant protein production. He was previously R&D Manager at Interface Biotech, leading several pipeline programs from preclinical to clinical phase. He has extensive experience in executive management of large national and international public-private partnerships. As CSO he is responsible for the overall R&D strategy and for external strategic collaborations across the Bioneer organization.
Jette Asboe Lassen
Jette Asboe LassenCBO, M.Sc.

Jette Asboe Lassen brings more than 20 years of business experience from her leadership roles in therapeutic and diagnostic life science companies in both the US and Europe. Prior to joining Bioneer, she served as Vice President and Head of Business Development and Alliance Management at Symphogen, a clinical stage oncology company developing antibody therapeutics. A commercial mindset combined with a robust understanding of science has enabled her to successfully guide product pipeline prioritization, transition ideas/programs into strong selling propositions, and execute and manage significant strategic alliances with pharmaceutical and diagnostic companies globally. She did her commercial training in the US and has since been the commercial lead during all stages of development from discovery through to product launch. As Chief Business Officer, she has the overall responsibility for Business Development and Marketing at Bioneer.
Sara Post
Sara PostChief CDMO Officer, Ph.D.

As Chief CDMO Officer at Bioneer, Sara is responsible for strategic development, operational scale-up and end-to-end delivery of our projects from R&D through GMP manufacturing and final product release.
She brings more than 20 years of experience with strategic leadership and organizational development from the manufacturing science, technical operations and CMC development area.
Prior to joining Bioneer, she served as Head of Global Manufacturing Science & Technology (MSAT) at Bavarian Nordic A/S after several manager and senior roles, where she worked with development, scale-up and technical transfer of manufacturing processes for both commercial vaccines and clinical trial material.
She has been responsible for strategies and successful execution of several large-scale tech transfers and scale-up of API and drug product manufacturing processes to support development and launch of commercial products.
Sara holds an MSc in Biochemistry from the University of Copenhagen and a PhD from the Steno Diabetes Center in Copenhagen.
Kia Norsker
Kia NorskerCFO, Cand.merc.aud

Kia Norsker has a M.Sc. (Business Economics & Auditing) from the Copenhagen Business School and nine years of experience as an external auditor at Deloitte and EY Denmark.
During those years she worked with both listed and medium sized private companies within different industries including life science and manufacturing.
Kia has an in-depth understanding of Bioneer and Bioneer’s business from her six years serving as external auditor for the company prior to her taking on the role as Bioneer’s CFO in 2021.
As CFO Kia has the overall responsibility for Finance and Accounting at Bioneer.
Søren Madsen
Søren MadsenProtein Expression, Dept. Head, Ph.D.

Heads the Protein Manufacturing Group in Hørsholm, managing R&D and customer relations, and handling projects from small-scale protein production to downstream processing.
Anette Müllertz
Anette MüllertzBioneer:FARMA, Dept. Head, Professor

Anette Müllertz heads the site of Copenhagen: Bioneer:FARMA, located at the Department of Pharmacy at the University of Copenhagen. She is also a professor in Pharmaceutical Design and Drug Delivery.
Pernille Skouboe
Pernille SkouboeRA/QA Manager, Adm. Dept. Head, M.Sc.

Responsible for quality assurance and regulatory compliance objectives within R&D services and GMP production.
Bjørn Holst
Bjørn HolstCellular Engineering & Disease Modelling, Dept. Head, Ph.D.

Heads the Biomedical Technology department in Hørsholm and is responsible for the advanced Disease Model group.
Charlotte Kvist Lorentzen
Charlotte Kvist LorentzenContract Manufacturing, Dept. Head, M.Sc.

Heads the Contract Manufacturing department at Bioneer, over 20 years of experience.
Monika Gad
Monika GadR&D Manager, Immunology and Cancer

R&D Manager, Immunology and Cancer.
Kenneth Thirstrup
Kenneth ThirstrupR&D Manager, Central Nervous System Assays

R&D Manager, Central Nervous System (CNS) Assays
Lasse Saaby
Lasse Saaby Head of Pharmaceutical Development

Head of Pharmaceutical Development
Matthias Manne Knopp
Matthias Manne KnoppR&D Manager, Pharmaceutical Development

R&D Manager , Pharmaceutical Development
Morten Madsen
Morten MadsenFacilities Manager

Facilities Manager

Board of Directors

Our Board has a profound insight into the pharmaceutical, biotech and medtech industries as well as in research and contributes to Bioneer’s position as a strong research-based development partner

Karin GarreChairman

Karin brings extensive leadership, change management, and drug development experience from over 30 years in the life science industry, encompassing roles in pharmaceutical and biotech companies such as Astra A/S, Novo Nordisk A/S, Genmab and most recently Symphogen A/S. In addition to various leading positions in line and project functions in pharmaceutical R&D she has held executive positions as c-suite member or CEO in industry and in the Danish health care sector. Karin came to Symphogen in 2018 and was appointed General Manager in 2020 when the company was acquired by Servier Pharmaceutical. In this role, she lead the change management process and integration of Symphogen into Servier’s global R&D function as the Center of Excellence for Antibodies. Upon completion, Karin decided to enter a new career path as of 2024. Karin is very much engaged in strategic and organizational performance aiming to combine science, technologies, and know-how, transforming opportunities into value for patients. She is focused on maintaining an inspiring and motivating working culture. Karin holds an MD from Copenhagen University. During her career she has held various board positions – currently she is on the board at Expres2ion Biotechnology and Cervello A/S. Further Karin runs her own advisory business, Garre Transformation.
Marianne ThellersenDep. Chairman

Marianne comes to the board with many years of biotech industry experience prior to her present position at DTU where she heads all activities concerning the creation of commercial value from scientific results. Marianne has an M.Sc. in Biotechnology from DTU and an e-MBA from CBS-SIMI. She first joined Novo Nordisk and later Novozymes where she held a range of positions related to research and innovation. Marianne was Program Director at CBS-Simi for two years before becoming SVP at DTU in 2012. Marianne is deeply engaged in how innovative research can be converted into viable societal and commercial value and is instrumental in creating a vibrant entrepreneuria environment at DTU campuses. Marianne represents DTU (the owner) and contributes to Bioneers societal and business activities with her many years of insight into technology transformation processes.
Bjarke Bak ChristensenBoard member

Bjarke Bak Christensen has a Ph.D. in Microbiology from the Technical University of Denmark (DTU) and worked as a research scientist at Danish Food and Veterinary Research Institute, where he became Head of Section in 2004. In 2007 he became Head of Research Division Microbiology and Risk Assessment at DTU Food. From 2010 to 2016 Bjarke headed Department of Food Science at University of Copenhagen (FOOD), which he left in order to become Head of Department of Biotechnology and Biomedicine at DTU, which is offering research and education within biotechnology, microbiology, biochemistry and pharma technology. Bioneer is benefitting from Bjarke’s profound knowledge and knowhow concerning novel trends and scientific developments in the food science, biotechnology and pharma areas.
Trine WinterøBoard member

Trine is a well known authority in the management of innovation processes and in the operationalization of novel business ideas at the interface of business, science and technology. Trine has a Ph.D in Molecular Genetics from The Royal Veterinary and Agricultural University where she later became Associate Professor. Her business career started in 2001 in her role as Innovation Manager of Symbion Science Park, and she later became the CEO of Symbion Management and Symbion Capital, an early stage venture fund. In 2008 she founded Medtech Innovation Consortium (MTIC) as CEO. At MTIC she was the main driver in building an entrepreneurial and creative product and service development environment between medtech companies, start-ups in the field, and health institutions. In 2016 she joined the University of Copenhagen in the role of Vice Dean for innovation at the Faculty of Health and Medical Sciences. Here, her task is to support the creation of a productive innovation system. Trine contributes to the Board with her many years of experience with public- private partnerships and in the management of innovation.
Mads LaustsenBoard member

Mads Laustsen is a well-known and highly respected Danish biotech CEO and entrepreneur with over 35 years of experience within large and medium sized biopharma companies as well as small life science start-ups. After 15 years combined at Novo Nordisk, Zymogenetics and Novozymes Mads co-founded CMC-Biologics where he was CEO for more than 10 years. Following the acquisition of CMC-Biologics by AGC, Mads became CMO of Symphogen and later co-founded Bactolife where he was CEO for 6 years before becoming an independent Strategic Advisor. Mads brings with him many years of valuable technical experience within Biologics development and manufacturing from the biotech and pharmaceutical industry and has extensive experience in managing both small and large companies. Furthermore, Mads possesses in-depth knowledge of initiating and operating biotech companies and currently serves on the Board of three other companies.
Lone VengBoard member

Lone Veng is an experienced, entrepreneurial and strategically minded C-Suite executive with a proven track record of building companies both as CEO and non-executive Director. Lone has 13 years of ‘Big Pharma’ experience from Lundbeck, Merck Research Laboratories and Leo Pharma where she has worked primarily with small molecule drug development. She was appointed CEO of Clinical Microbiomics in 2015 and was CEO of Resother Pharma from 2017 to 2023. From her time at these companies, Lone brings comprehensive experience within project leadership including setting business and therapeutic area strategies. Her leadership approach focuses on formulating and clearly communicating strategy, optimizing the business to deliver quality, and on building competence and enthusiasm in organizations. Currently, Lone sits on the Board of two other companies.
Lasse SaabyBoard member

Pharmaceutical Development, Head of Operations, Ph.D., Bioneer
Monika GadBoard member

Cellular Engineering and Disease Modelling, Team Manager, Ph.D., Bioneer.
Marianne Imer BønnelyckeBoard member

Laboratory Technician, Bioneer.

GTS

From science to societal value

Bioneer A/S is a not-for-profit organization and a subsidiary of the Technical University of Denmark (DTU). It is approved by the Danish Ministry of Science and Technology as an authorized provider of technological services – a GTS entity.

Our public mission is two-fold. First, to provide tools and technologies that facilitate early implementation of new therapeutic strategies in the Danish health sector. Second, to contribute to making Denmark a front-runner in very early commercialization of biomedical research as a means to grow the Danish biotech industry.

GTS is the Danish Association of Research and Technology Organizations that connects technology and businesses.

The seven Danish government-approved Research and Technology Organization (GTS institutes) play a key role in the Danish innovation system as the link between technology and business. They seek to make new technological methods applicable to businesses and promote businesses uptake of new technology.

Read more about the GTS entities here.

The 7 Danish GTS institutes are Alexandra Instituttet , DBI , DFM, DHI, Teknologisk Institut, Force Technology and Bioneer.

Latest news

Discover and read our latest news.